The N-a-acetyltransferase NatB, composed in Saccharomyces cerevisiae by the Nat3p and Mdm20p subunits, is an important factor for yeast growth and resistance to several stress agents. However, the expression and functional role of the mammalian counterpart has not yet been analysed. Here, we report the identification of Nat3p human homologue (hNAT5/hNAT3) and the characterization of its biological function. We found that hNAT5/hNAT3 silencing in HeLa cells results in inhibition of cell proliferation and increased sensitivity to the pro-apoptotic agent MG132. Moreover, inhibition of hNAT5/hNAT3 expression induces p53 activation and upregulation of the antiproliferative protein p21(WAF1/CIP1). The changes of the cellular transcriptome after hNAT5/hNAT3 knockdown confirmed the involvement of this protein in cell growth and survival processes. Among the genes differentially expressed, we observed upregulation of several p53-dependent antiproliferative and pro-apoptotic genes. In the c-myc transgenic mice, which is a model of inducible hepatocarcinoma, we found that hNAT5/hNAT3 was upregulated when the tumour was induced. In accordance with this observation, we noticed increased hNAT5/hNAT3 protein level in neoplastic versus non-neoplastic tissue in a high proportion of patients with hepatocellular carcinoma. Consequently, our results suggest that hNAT5/hNAT3 is required for cellular proliferation and can be implicated in tumour growth.
Introduction
Protein acetylation is an important modification relevant for several cellular processes and cancer development that can be catalysed by two different groups of protein acetyltransferases. Almost 90% of mammalian proteins and 50% of yeast proteins are N-terminal acetylated, but there are only a few examples that demonstrate the biological relevance of this cotranslational modification . In yeast, three major N-a-acetyltransferase (NAT) activities, NatA, NatB and NatC, have been described according to the distinct N-terminal sequences they recognize. These acetyltransferase activities are catalysed by protein complexes that contain at least a catalytic subunit (Ard1p, Nat3p, Mak3p) and an auxiliary subunit required for activity. Moreover, it has been shown that a deficiency in NatA and NatB activities in yeast are related to growth and mating defects (Polevoda et al., 1999) .
The function of the NatA complex has been analysed in humans and mice. It has been observed that there is a higher expression of human arrest defective 1 (hARD1) and N-acetyltransferase human (NATH) in tissues and cells that have a stronger proliferative status (Fluge et al., 2002; Line et al., 2002; Arnesen et al., 2005b) . The amount of hARD1 and NATH mRNA in most human adult tissues is lower than in highly proliferative organs such as testis (Fluge et al., 2002) . In the developing brain in mice, these genes are highly expressed in areas of cell division and migration and are downregulated as neurons differentiate (Gendron et al., 2000; Sugiura et al., 2001 Sugiura et al., , 2003 . Moreover, in humans, NATH is highly expressed in gastric and thyroid cancer, this protein probably being the determining factor for the level of functional NATH-hARD1 complexes present in the cells (Arnesen et al., 2005b) .
It has also been reported that hARD1 and NATH are relevant for cell-cycle progression in vitro, as the inhibition of their expression reduces cell proliferation (Fisher et al., 2005; Arnesen et al., 2006b) . NATH and hARD1 inhibition also induces cell apoptosis and increases the susceptibility of the cells to the apoptotic inducer daunorubicine (Arnesen et al., 2006b) . Therefore, inhibition of NatA activity in mammalian cells results in defects in cell growth and survival as observed in yeast.
In yeast, NatB complex is formed by the catalytic subunit Nat3p (Polevoda et al., 1999) and the associated subunit Mdm20p Singer and Shaw, 2003) , both being proteins necessary for the acetylation of NatB substrates such as tropomyosin and actin. Deletion of either NAT3 or MDM20 genes results in the reduction of cell growth and mating and increased sensitivity to DNA-damaging agents. It has been suggested that Nat3p and Mdm20p might have an important function in cellular proliferation in yeast because proteins involved in DNA processing and cell cycle progression are overrepresented among the predicted substrates of NatB (Caesar et al., 2006) .
In this work, we have investigated the biological function of the human homologue of yeast Nat3p protein, denominated as hNAT5/hNAT3, which has not been previously characterized. We report that inhibition of hNAT5/hNAT3 expression using small interfering RNAs (siRNA) induces p53-mediated growth arrest in HeLa cells and sensitizes the cells to MG132-induced apoptosis. This effect correlates with stronger expression of hNAT5/hNAT3 in mouse and human hepatocellular carcinoma, suggesting a significant function of hNAT5/ hNAT3 in cell survival, cell proliferation and probably in liver cancer progression.
Results
hNAT5/hNAT3, the human homologue of yeast NAT3, is expressed in cell cytoplasm in association with ribosomes In this work, we intended to study the biological function of yeast NAT3 human homologue, named hNAT5 by the HUGO Gene Nomenclature Committee and designated by us as hNAT5/hNAT3 (to distinguish it from the previously described hNAT5/hSAN (Arnesen et al., 2006a) , a homologue of the yeast NAT5 gene, named NAT13 by the HUGO Gene Nomenclature Committee). This protein is distinct from human NAT3 that belongs to a different protein family, the arylamine N-acetyltransferase family (Sim et al., 2008) , which it is not present in yeast. Figure 1b shows the sequence homology between the human proteins hNAT5/hNAT3, hNAT13/hNAT5/hSAN, hARD1 (all of them belonging to the ARD1 protein family) and the yeast protein Nat3p. The highest homology between yeast Nat3p and Figure 1 (a) NatA and NatB enzymatic complexes identified subunits in yeast and human. (b) Alignment of human hNAT5/hNAT3 (UniprotKB P61599), human ARD1 (UniprotKB P41227), human NAT13/hNAT5 (UniprotKB Q9GZZ1) and yeast Nat3p (UniprotKB Q06504) subunit of NatB complex. Identical amino acids are inserted in black boxes and in light grey boxes if they are identical only in some sequences. Conserved aa are included in dark grey boxes. Motifs A and B are involved in acetyl CoA binding (Neuwald and Landsman, 1997; Dutnall et al., 1998) .
N-a-acetyltransferase 5 and cellular proliferation A Ametzazurra et al human ARD1 protein family members is with hNAT5/ hNAT3 protein (38.6% identity and 55.8% similarity) compared with 20.7% identity (32.1% homology) with hARD1 (the biggest protein in the family) and 13% identity (33.3% homology) with hNAT13/hNAT5/SAN proteins, having the region-spanning motifs A and B high degree of similarity. Therefore, this analysis confirms that hNAT5/hNAT3 protein is the human homologue of the yeast Nat3p protein.
The yeast N-terminal acetyltransferases are associated with ribosomes (Gautschi et al., 2003; Polevoda et al., 2008) , and the NatA complex is located in mammalian cells mainly in the cytoplasm coupled to polysomes (Arnesen et al., 2005a) . hNAT5/hNAT3 cellular localization in HeLa cells was examined by immunofluorescence with a commercial antibody against hNAT5/hNAT3. As it can be observed in Figure 2a , this protein is located in the cytoplasm of the cell colocalizing with the ribosomal protein S6 (Figure 2a4 , yellow colour). To verify the interaction between hNAT5/hNAT3 and the ribosomes, we isolated polysomes by ultracentrifugal fractionation (Arnesen et al., 2005a) and analysed the presence of hNAT5/hNAT3 in the polysomal fraction (Figure 2b ). These results indicate that hNAT5/hNAT3 protein is not exclusively located in the polysomes as it is the case of the ribosomal protein S6 (RPS6), but it is associated with ribosomes in a high proportion. Thus, our data indicate that hNAT5/hNAT3 is a cytoplasmic protein preferentially localized in association with ribosomes.
hNAT5/hNAT3 knockdown inhibits cell proliferation and sensitizes the cells to pro-apoptotic stimuli We designed specific siRNAs against hNAT5/hNAT3 to inhibit its expression in HeLa cells to dissect its function. Knockdown of endogenous hNAT5/hNAT3 in HeLa cells was obtained by infection with various adenoviruses that express four different hNAT5/hNAT3 siRNAs. Two different siRNAs (siRNA2 and siR-NA490) were found to be effective at reducing mRNA and protein level of hNAT5/hNAT3, whereas the other two siRNAs (siRNA350 and siRNA592) showed no effect (Figures 3a and b) . We then explored if hNAT5/hNAT3 has NAT activity and if this activity is reduced after inhibiting hNAT5/hNAT3 expression. We used an in vitro NAT assay described previously (Sugiura et al., 2003 , Arnesen et al., 2005a with some modifications. As tropomyosin has been described as a substrate for NatB in yeast Singer and Shaw, 2003) and as mammalian tropomyosin-1 is acetylated in its Nterminal end , we used the N-terminal 20 amino acids of human tropomyosin-1 as substrate for NAT activity. We observed incorporation of radioactivity to the substrate peptide in the presence of hNAT5/hNAT3 (Figure 3c ). However, when we used a tropomyosin-1 N-terminal peptide with a change at position þ 2 (D-A) as substrate, the incorporation of radioactivity was reduced drastically (Figure 3c ). Moreover, we found that when the expression of hNAT5/hNAT3 in HeLa cells was inhibited, there was a marked decrease of cellular NAT activity.
To determine whether the decrease of hNAT5/ hNAT3 protein reduces cell proliferation, we measured BrdU incorporation and we observed a marked decrease after inhibiting hNAT5/hNAT3 production (20%) as compared with control cells (36.7% in HeLa cells and 34% in AdsiRNA350-infected cells) (Figure 4a ). We then analysed the effect of inhibiting hNAT5/hNAT3 expression on cell cycle progression. We found that this manoeuvre caused a reduction in the fraction of cells in G0/G1 phase together with an increase of cells in S phase and an accumulation of cells in G2/M phase ( Figure 4b ). These findings show that hNAT5/hNAT3 is necessary for proper cellular proliferation.
p53 is a key component of the cellular machinery that controls cell cycle progression. Upregulation of p53 is associated with induction of growth arrest (Yu et al., 1999; Vousden, 2000) . Thus, we examined p53 expression after siRNA2 and siRNA350 expression in HeLa cells. As shown in Figure 4b , inhibition of hNAT5/hNAT3 expression strongly increases p53 levels with a marked increase of p53 Ser 15 and p21 levels in AdsiRNA2-treated cells, indicating that growth arrest is linked to p53 upregulation and p21 overexpression ( Figure 4c ).
The growth arrest induced by blocking hNAT5/ hNAT3 expression is not associated with increased spontaneous apoptotic rate (data not shown). To see whether decreased levels of hNAT5/hNAT3 could render the cells more susceptible to apoptotic insults, non-infected HeLa cells and cells transduced with AdsiRNA2 or AdsiRNA350 were treated with MG132, a proteasome inhibitor, for 8 and 24 h. As shown in Figure 4d , cells infected with AdsiRNA2 were more susceptible to MG132-induced apoptosis than non-infected cells or cells transduced with AdsiR-NA350. At 24 h of incubation with MG132, the number of apoptotic cells was near 20% in those infected with AdsiRNA2, whereas it was below 2% in non-infected cells or cells transduced with AdsiRNA350.
Genes differently expressed after hNAT5/hNAT3 knockdown To gain insight into hNAT5/hNAT3 function and the causes of the cell cycle arrest and increased sensibility to pro-apoptotic stimuli following hNAT5/hNAT3 inhibition, we performed a microarray expression profiling experiment. We used Affymetrix U133A microarrays and compared gene expression pattern in HeLa cells 56 h after infection with AdsiRNA2 or AdsiRNA350 or without infection. A total of 275 genes were differently expressed (fold change X2, Pp0.05) in AdsiRNA2-infected cells compared with control group (noninfected HeLa cells and siRNA350-expressing cells). Only 42 of these genes were upregulated, whereas the majority (85%) was downregulated.
We carried out an in silico functional analysis to identify biological processes affected by hNAT5/hNAT3 downregulation comparing the percentage of differently expressed genes with a given gene ontology annotation with the percentage of genes on the Affimetrix U133A GeneChip with the same annotation. Figure 5a shows the gene ontology categories that were significantly enriched in our list of differently expressed genes. We found that the most prominently enriched categories are related to cell cycle and cancer, suggesting that hNAT5/ hNAT3 knockdown mainly affects cell cycle progression.
Because, as mentioned, the predominant effect of hNAT5/hNAT3 inhibition was to induce cell cycle arrest, we analysed in detail some of the differently expressed genes related to cell cycle progression and confirmed their expression by reverse transciptase-PCR. For this study, HeLa cells were mock-infected or infected with AdsiRNA2 or AdsiRNA350 for 33, 48 and 72 h. We analysed the expression of 21 genes: those presented in Figure 5b plus SMARCA1, PLK4, CCND3, RANBP2 and DDB2. Of these genes, 16
( Figure 5b ) showed differential expression after hNAT5/hNAT3 inhibition, 6 being upregulated and 10 downregulated. Five of the 6 upregulated genes have N-a-acetyltransferase 5 and cellular proliferation A Ametzazurra et al been described as p53 targets indicating the relevance of p53 upregulation for the induction of cell growth arrest after hNAT5/hNAT3 knockdown. One of these genes, p21(WAF1/CIP1), which is highly upregulated, has been reported as a strong inducer of growth arrest (Vousden, 2000) . Most of the downregulated genes are implicated in promoting cell cycle progression. It should be noted that USP16, a gene whose inhibition reduces cell growth rate (Joo et al., 2007) , is highly downregulated when hNAT5/hNAT3 is blocked.
Expression of hNAT5/hNAT3 in tumour tissue As inhibition of hNAT5/hNAT3 expression has a marked impact on cell growth, we analysed the expression of this gene in a murine model of liver cancer (PK-myc transgenic mice) and in tissue samples from patients with hepatocellular carcinoma. The animal model is based on the expression in the murine liver of the oncogene c-myc regulated by L-pyruvate kinase promoter (Cartier et al., 1992 (Cartier et al., , 1994 , which is induced by administration of diets with high carbohydrate content. We observed that hNAT5/hNAT3 protein expression was slightly higher in transgenic mice than in wild-type animals when maintained on a regular diet. But a marked increase in the expression of hNAT5/ hNAT3 protein was observed in the neoplastic livers of transgenic mice fed for 7 months with a carbohydraterich diet (Figure 6a ). This increment is not induced directly by c-myc because overexpression of c-myc in cell lines is unable to upregulate hNAT5/hNAT3 expression (data not shown). Carbohydrate-rich diet, however, has no effect on hNAT5/hNAT3 expression and tumour induction in wild-type animals nor in transgenic animals fed for 1 and 5 months with a carbohydrate-rich diet (a period that antedates the development of tumours; data not shown). When we analysed separately tumour and non-tumour tissues from transgenic mice that had developed liver cancer, we observed that in two of three cases, there was a higher expression of hNAT5/hNAT3 protein in the tumour as compared with the non-tumour tissue (Figure 6b) .
Subsequently, we studied hNAT5/hNAT3 expression in tumour and non-tumour liver tissue from six patients with hepatocellular carcinoma. We observed higher abundance of hNAT5/hNAT3 protein in the tumour as compared with non-tumour tissue in four patients (66%), whereas it was similar in the other two patients (Figure 6c ).
Discussion
In yeast, Nat3p, hNAT5/hNAT3 homologue, mediates protein N-a-acetyltransferase B (NatB) activity being implicated in cellular proliferation and response to stress stimuli (Polevoda et al., 1999 . Here, we show in humans that hNAT5/hNAT3 catalyses in vitro acetylation of a peptide corresponding to the N-terminal end of the human tropomyosin-1, that it has been described to be N-terminal-acetylated in mammals and yeast and that it is a substrate of yeast hNAT5/NAT3 homologue, Nat3p. In agreement with the results observed in yeast , the tropomyosin-1 aspartic residue at position þ 2 is important for the peptide to be an hNAT5/hNAT3 substrate, as its substitution by alanine inhibits its in vitro acetylation by hNAT5/hNAT3. We cannot exclude that this enzymatic reaction is catalysed by an enzymatic complex, as it occurs in yeast Singer and Shaw, 2003) , but we have shown that hNAT5/hNAT3 is mediating this reaction in vitro.
hNAT5/hNAT3 protein colocalizes with the ribosomal protein S6 and is located preferentialy in the polyribosomes after ultracentrigugal purification, suggesting an association with ribosomes, as has been demonstrated for its yeast homologue, Nat3p, and the NATH-hARD1 complex (Arnesen et al., 2005a) . N-a-acetylation activity catalysed by these enzymes is a cotranslational process that modifies the proteins as they emerge from the ribosome affecting their function, stability and interaction with other molecules . It has been reported previously in humans that siRNA-mediated inhibition of hARD1 blocks cell division (Fisher et al., 2005; Arnesen et al., 2006b) and that ARD1 and NAT3 yeast knockout strains present delayed cell cycle progression (Polevoda et al., 1999) . It seemed therefore that some of the targets of hNAT5/hNAT3 might be involved in cell cycling. Indeed, we observed that the knockdown of this factor negatively affects cell proliferation, causing G2/M phase growth arrest of HeLa cells. Interestingly, this effect was associated with accumulation of p53 and p21(WAF1/CIP1) and increased phosphorylation of p53 at ser-15, which is the most frequent phosphorylation site of p53 in response to stress signals (Bode and Dong, 2004; Lavin and Gueven, 2006) . Clustering of the differently expressed genes after hNAT5/hNAT3 knockdown shows that most of the genes are associated with functional categories related to cell cycle progression and cancer, indicating the relevance of this protein for cell proliferation. Analysis of the cellular transcriptome after hNAT5/hNAT3 inhibition shows altered expression of many genes (85% of genes with altered expression are downregulated) with a pattern that is compatible with p53-mediated growth arrest (Kho et al., 2004; Spurgers et al., 2006) . p53 not only induces inhibitors of cell proliferation (p21(WAF1/CIP1)), but also represses a diversity of genes that regulate proliferation at different phases of the cell cycle (CCNE2, TOP2A, NEK2). Several of the upregulated genes in hNAT5/hNAT3 RNAi-treated cells are p53 targets (p21(WAF1/CIP1), ATF3, PLAB/ GDF15/MIC-1, PLK3) indicating a key function of p53 activation in the inhibition of cell growth following hNAT5/hNAT3 knockdown. In particular, there is a remarkable upregulation of p21(WAF1/CIP1), a key executor of p53-mediated repression of proliferation (Liu and Lozano, 2005) , associated with cell cycle arrest (Cheung et al., 2004; Agarwal et al., 2006) . Moreover, the blockade of hNAT5/hNAT3 expression leads to downregulation of genes that promote cell proliferation, such as CDKN3, DEK, NEK2, TOP2A and NAP1L1 (Simon et al., 1994; Braun et al., 1998; Wise-Draper et al., 2006; Rellos et al., 2007) , in keeping with the antiproliferative effect of the manoeuvre. These changes remind the overexpression of antiproliferative molecules together with downregulation of proliferative genes observed after inhibition of hARD1 using shRNAs. However, the genes altered following hARD1 inhibition differ from those whose expression is modified after hNAT5/hNAT3 knockdown (Fisher et al., 2005) . These differences could explain the finding that whereas there is an accumulation of cells in the G2/M phase when hNAT5/hNAT3 is inhibited, there is a G1 cell cycle arrest when hARD1 expression is blocked (Lim et al., 2006) . It seems therefore that hARD1 and hNAT5/ hNAT3 are implicated differently in the regulation of cell proliferation, probably because they acetylate different sets of proteins. Another divergence between the N-a-acetyltransferase hARD1 or NATH and hNAT5/hNAT3 is that knockdown of the former reduces cell viability in HeLa cells (Arnesen et al., 2006b) , whereas inhibition of hNAT5/hNAT3 decreases cell growth without increasing apoptosis rate. However, hNAT5/hNAT3 inhibition sensitizes HeLa cells to proapoptotic stimuli, an effect that resembles the changes observed in yeast after deleting NAT3, a genetic manipulation that makes this microorganism more sensitive to several DNA-damaging agents (Polevoda et al., 1999) . The increased sensitivity to pro-apoptotic agents such as MG132 is not accompanied by changes in the levels of BAX or BCL-2 (data not shown), but several p53 pro-apoptotic genes (ATF3, PLK3, FDXR, PLAB/GDF15/MIC-1) (Kannan et al., 2001; Xie et al., 2001; Liu and Chen, 2002; Lim et al., 2007) were upregulated when hNAT5/hNAT3 expression was inhibited. These findings are also reminiscent of the increased sensitivity to environmental stress when yeast strains were deleted of Nat3p, the yeast homologue of hNAT5/hNAT3.
As hNAT5/hNAT3 appears to be critical for cell proliferation, we examined if the expression of this protein was altered in experimental models of liver cancer and in human hepatocellular carcinoma. In the PK-myc transgenic mice, we observed a marked upregulation of hNAT5/hNAT3 after 7 months exposure to a carbohydrate-rich diet, which stimulates c-myc expression and tumour development, suggesting a function of hNAT5/hNAT3 in liver carcinogenesis. This notion is further supported by the finding of higher hNAT5/hNAT3 levels in tumour than in non-tumour tissue in animals with hepatocellular carcinoma. Moreover, the implication of hNAT5/hNAT3 in tumour development was also suggested by increased levels of the protein in malignant tissue of 66% of patients with hepatocellular carcinoma.
In conclusion, hNAT5/hNAT3 function is essential for cell cycle progression and resistance to pro-apoptotic insults. Inhibition of hNAT5/hNAT3 expression causes cell cycle arrest in association with p53 induction. hNAT5/hNAT3 is overexpressed in preneoplastic liver lesions and in experimental and clinical liver cancer. Our data reveal an up-to-now unrecognized role of hNAT5/ hNAT3 in cell proliferation and are indicative of a role in neoplastic growth, suggesting that this might be a novel target for liver cancer therapy.
During the preparation of this manuscript, Starheim et al. (2008) have presented data that confirm many of the results presented in this work, although there are some differences that could be caused by the use of different methodological approaches.
Materials and methods

siRNAs
The siRNAs sequences (Table 1) were designed (Reynolds et al., 2004) and inserted into the pMSCV3SUPER vector, which contains polymerase-III H1-RNA gene promoter (Brummelkamp et al., 2002) . The target sequences for hNAT5/hNAT3 were chemically synthesized (Sigma-Proligo, Evry, France) as complementary oligonucleotides. The selected sequences were annealed and inserted into pMSCV3SUPER vector (a gift from Dra. Puri Fortes, CIMA, Pamplona, Spain), leading to pMSCV3SUPERsiRNA constructs.
Adenovirus production
Adenovirus has been used for hNAT5/hNAT3 siRNAs expression in HeLa cells. The siRNA expression cassettes were obtained from pMSCV3SUPERsiRNA constructs and cloned in the pAdlox vector after XhoI/EcoRI digestion.
E1-substituted recombinant adenoviruses were constructed by the Cre-lox recombination system using psi5 adenovirus as a donor virus (Hardy et al., 1997) obtaining the following pAdsiRNA adenoviruses: pAdsiRNA2, pAdsiRNA350, pAdsiRNA490 and pAdsiRNA592. Adenovirus was amplified in 293 cells.
Cell culture and infections with the siRNA-expressing adenoviruses Human HeLa and 293 cell lines were purchased from the ATCC and 293 Cre4 cell line was provided by Dr Hardy. All the cell lines were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. Cre4 cells were also supplemented with 500 mg/ml G418. All reagents were obtained from Gibco-BRL (Paisley, UK).
Infections with hNAT5/hNAT3 siRNA-expressing adenoviruses were performed in HeLa cells. The day before infection, 150 000 HeLa cells were plated in a six-well plate and infection was performed in Dulbecco's modified Eagle's medium-2% fetal calf serum at a multiplicity of infection of 10.
Immunofluorescence HeLa cells grown on cover glasses were fixed with cold methanol and incubated with hNAT5/hNAT3 polyclonal antibody (Genway Biotech, San Diego, CA, USA) or S6 Ribosomal Protein antibody (Cell Signalling Technology, Beverly, MA, USA). The secondary antibodies used were Cy3-conjugated polyclonal anti-IgY (Abcam, Cambridge, UK) and FITC-conjugated anti-rabbit IgG (Sigma-Aldrich, Steinheim, Germany). Images were acquired on an Axiovert 200M microscope with a Zeiss confocal LSM 510 META (Zeiss, Jena, Germany).
MBP-hNAT5/hNAT3 was produced by the standard methods used in the pMAL protein fusion and purification system (New England Biolabs, Hitchin, Hertfordshire, UK).
RNA isolation and gene expression analyses
Total RNA from cultured cells was extracted using 0.5 ml of the Ultraspec reagent (Biotecx, Houston, TX, USA) following the manufacturer's protocol.
For cDNA synthesis, 2 mg of RNA were treated with DNase I (Invitrogen, Prat de Llobregat, Barcelona, Spain) before reverse transcription with Moloney murine leukaemia virus reverse transcriptase (Invitrogen) in the presence of RNase-OUT (Invitrogen).
Real-time PCR was used for quantification of gene expression and was performed in an iCycler (Bio-Rad Laboratories, Hercules, CA, USA) using 2 ml of cDNA per sample and 18 ml of the reaction mixture that included 0.3 mM of each sense and antisense primer (Table 2 ) and the iQ SYBR Green Supermix (Bio-Rad Laboratories).
Results were normalized to control gene GAPDH, and the amount of each transcript was expressed by the formula: 2
CtðGAPDHÞ2CtðgeneÞ
, C t being the point at which fluorescence rises appreciably above background fluorescence.
Protein extraction and western blot analysis
Liver protein extracts were obtained as follows: tissue was homogenized in 200 ml of lysis buffer containing 10 mM Tris-Cl, pH 7.4, 1 mM KCl, and 0.1 mM EGTA, supplemented with 1 mg/ml aprotinin, 1 mM phenylmethanesulphonylfluoride (PMSF), 10 mg/ml trypsin inhibitor, 10 mg/ml leupeptin, 1 mg/ ml pepstatin, 1 mM Na 3 VO 4 and 1 mM NaF. Protein extracts were collected by centrifugation at 100 000 g for 45 min and supernatants were stored at À80 1C.
To extract protein from cultured cells, the cells were collected in 100 ml of RIPA solution (150 mM NaCl, 50 mM Tris pH 7.5, 0.1% SDS, 1% Triton X-100, 0.5% sodium deoxycholate, 10 mM NaF, 1 mM Na 3 VO 4 and a protease inhibitor cocktail obtained from Roche). Protein extracts were collected after sonication and centrifugation at 16 000 g for 15 min, and supernatants were stored at À80 1C.
Total liver protein extracts (50 mg) or cultured cells protein extracts (20 mg) were loaded in SDS-polyacrylamide gels, and after electrophoresis, the proteins were transferred to nitrocellulose membranes (Bio-Rad Laboratories), detected by incubation with specific antibody. Protein bands were visualized using the enhanced chemiluminescence detection system (Perkin Elmer, Boston, MA, USA) and membranes were autoradiographed.
Antibodies used were as follows: chicken anti-hNAT5/ hNAT3 from Genway Biotech, mouse anti-GAPDH from Biogenesis (Bournemouth, UK), mouse anti-p53 (DO-1), rabbit anti-p53 Ser15 (16G8) and goat anti-p21(WAF1/CIP1) from Santa Cruz Biotechnology (Santa Cruz, CA, USA), anti-rabbit IgG HRPO from Cell Signalling, anti-goat IgG HRPO and anti-mouse IgG HRPO from Sigma (Tres Cantos, Madrid, Spain), rabbit anti-IgY from Upstate (Lake Placid, NY, USA) and rabbit anti-IgY HRPO from Pierce (Rockford, IL, USA). GGAGGGCAGTCAGTCTCAAG  AGCAAGGGCTACCAAGGATT  60  DDB2  CTCCTCAATGGAGGGAACAA  GTGACCACCATTCGGCTACT  60  DEK  ACGGAACAGTTCTGGAATGG  TGGTGGCTCCTCTTCACTTT  60  FDXR  TGGAAATTCCTGGTGAGGAG  CTCAGGTGGGGTCAGTAGGA  60  NAP1L1  TGGTTCAGGAACACGATGAA  ATCTGGCACCCTGTACAACC  60  NBS1  TTGGTTGCATGCTCTTCTTG  GGCTGCTTCTTGGACTCAAC  60  NEK2  AACCAGCCAATGTTTTCCTG  GCCTGAATTTGCCTTCTCTG  60  NMA  AGCTTTCACGGACACCATTC  ATCGTTGCTGAGGTCTGCTT  60  PLAB/GDF15/MIC-1  CTCCAGATTCCGAGAGTTGC  AGAGATACGCAGGTGCAGGT  60  p21  GAGACACCACTGGAGGG  TTGGAGTGGTAGAAATCTG  55  RAD50  CTTGGATATGCGAGGACGAT  CCAGAAGCTGGAAGTTACGC  60  RANBP2  GACCCCAATTTCAAGGGATT  CGGGCATTTGAACTACTGGT  60  SMARCA1  AGACTGGAACCCACAGGTTG  TCCTCTTTTGCCAGCTTGTT  60  STK18  CCACAGACAACAATGCCAAC  GCAGATTCCCAAACCACTGT  60  TOP2A  AATCTCAGAGCTTCCCGTCA  TGCCTCTGCCAGTTTTTCTT  60  USP16  ACTCCAAAGCCAGCAGAGAA  CGGTTATTTGGCAAGGAGAA  60 N-a-acetyltransferase 5 and cellular proliferation A Ametzazurra et al
Isolation of polysomes
Polysomes were isolated as described by Arnesen et al. (2005a) . Briefly, 10 7 HeLa cells were cross-linked using dithiobis (Pierce) according to manufacturer's instructions. Afterwards cells were lysed in 1 ml of lysis buffer (0.25 M sucrose, 130 mM KCl, 10 mM triethanolamine, 5 mM magnesium acetate, 0.25% TritonX-100 and 1 mM PMSF) on ice for 15 min and centrifuged at 1500 g for 10 min. The supernatant (CS) was ultracentrifugated at 436 000 g for 25 min in a TLA 102.2 rotor (Beckman, Geneva, Switzerland) through 0.4 ml of sucrose 25% obtaining a post-ultracentrifugal supernatant (USN) and a polysomal pellet (POL).
N-terminal acetyltransferase assay
The NAT assay was performed basically as described previously (Sugiura et al., 2003; Arnesen et al., 2005a) , but using hNAT5/hNAT3 immunoprecipitated complexes that were incubated with 138 ml of 0.2 M K 2 HPO 4 (pH 8.1), 10 ml of the substrate peptide (0.5 mM) and 1 mCi of [ 3 H]acetyl-CoA (99.9 GBq/mmol, GE Healthcare) for 2 h at 37 1C. The samples were centrifuged and the supernatant was incubated with SP-Sepharose (50% in 0.5 M acetic acid) for 10 min on a rotor before washing the SP-Sepharose three times with acetic acid 0.5 M and once with methanol. The radioactivity incorporated in the peptides was determined by scintillation counting.
Cell proliferation assay
HeLa cells were seeded in 15-mm cover glasses and infected with siRNA-expressing adenovirus pAdsiRNA2 or pAdsiR-NA350 for 24, 48 and 72 h, BrdU labelled for 1 h and processed using the 5-bromo-2 0 -deoxy-uridine labeling and detection kit I (Roche Applied Science, Penzberg, Germany) following the manufacturer's instructions.
Cell cycle analysis
HeLa cells were harvested after 72 h of infection with the adenovirus pAdsiRNA2 or pAdsiRNA350 and processed using the CycleTEST PLUS DNA reagent kit (Becton Dickinson, San Jose, CA, USA) following the manufacturer's instructions. Flow cytometric analysis of the different samples was performed using BD FACScalibur flow cytometer, and DNA content was analysed using the MODFIT software.
TUNEL assay
HeLa cells were incubated in 15-mm cover glasses and infected with adenovirus pAdsiRNA2 or pAdsiRNA350 for 48 h before adding the proteasome inhibitor MG132 (5 mM) (Calbiochem, Darmstadt, Germany) for an additional 8 or 24 h. Cells were fixed in 4% phosphate-buffered paraformaldehyde (pH 7.4). TUNEL assay was performed using the in situ cell death detection kit (Roche Applied Science) according to the manufacturer's instructions. Cell apoptosis percentage was obtained as indicated in cell proliferation assay.
Transcriptome analysis after inhibition of hNAT5/hNAT3 expression Microarray hybridization was performed at Progenika Biopharma SA (Bilbao, Spain), using tools obtained from Affymetrix and according to the manufacturer's instructions (Affymetrix, Santa Clara, CA, USA). HeLa cells grown in 100-mm culture plates were uninfected or infected with the pAdsiRNA2 or pAdsiRNA350 adenoviruses for 56 h in duplicate and analysed using a Human Genome U133A 2.0 array (Affymetrix), and the software used for analysing the chips and results processing was the Gene Chip Operating Software (GCOS 1.2, Affymetrix).
The study of differentially expressed genes between the different groups was performed with the Ingenuity Pathways Analysis software (Ingenuity Systems Inc., Redwood City, CA, USA).
Liver tissue specimens from mice and patients Liver tissue samples from transgenic 129 mice expressing the c-Myc oncogene under the control of the L-type pyruvate kinase gene promoter (PK-myc transgenic mice) were used (Cartier et al., 1992 (Cartier et al., , 1994 . Liver tissue samples were obtained from transgenic mice fed with a carbohydrate-rich diet with tumours of 6.24 ± 3.53 mm in diameter or those fed with a normal diet for 7 months, which have no tumour. Also liver specimens were obtained from wild-type 129 mice fed with normal or carbohydrate-rich diet.
Neoplastic (tumour) and non-neoplastic (non-tumour) paired liver samples were obtained from six male patients with hepatocellular carcinoma attended in the University Clinic of Navarra (Pamplona, Spain) with previous informed written consent. The selection of the tissue was based on macro-and microscopic examination.
